# A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events

> **NCT07729475** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Elevated Lipoprotein(a)

## Interventions

- **DRUG:** SAL0137 Dose 1
- **DRUG:** SAL0137 Dose 2
- **DRUG:** SAL0137 Dose 3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07729475
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-27
- **Primary completion:** 2026-12-12
- **Final completion:** 2027-04-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729475, "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07729475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*